Evolving knowledge and therapy of inflammatory bowel disease

[1]  E. Chuang,et al.  A Phase II dose ranging, double‐blind, placebo‐controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left‐sided ulcerative colitis , 2006, Alimentary pharmacology & therapeutics.

[2]  P. Rutgeerts,et al.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. , 2006, Gastroenterology.

[3]  S. Hanauer,et al.  Continuing Medical Education Exam 3: February 2006: Human Anti-Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial , 2006 .

[4]  S. Targan,et al.  Natalizumab induction and maintenance therapy for Crohn's disease. , 2005, The New England journal of medicine.

[5]  R. D. Hatton,et al.  Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages , 2005, Nature Immunology.

[6]  T. Wynn.  TH-17: a giant step from TH1 and TH2 , 2005, Nature Immunology.

[7]  M. Sherman,et al.  Following the TRAIL from hepatitis C virus and alcohol to fatty liver , 2005, Gut.

[8]  S. Schreiber,et al.  A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. , 2005, Gastroenterology.

[9]  C. Hawkey,et al.  Rdp58 Is a Novel and Potentially Effective Oral Therapy for Ulcerative Colitis , 2005, Inflammatory bowel diseases.

[10]  J. Berger,et al.  Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences. , 2005, The New England journal of medicine.

[11]  K. Tyler,et al.  Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. , 2005, The New England journal of medicine.

[12]  S. Atlas,et al.  Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. , 2005, The New England journal of medicine.

[13]  P. Rutgeerts,et al.  Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. , 2005, The New England journal of medicine.

[14]  A. Cohen,et al.  Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. , 2005, The New England journal of medicine.

[15]  R. Playford,et al.  Trial of trefoil factor 3 enemas, in combination with oral 5‐aminosalicylic acid, for the treatment of mild‐to‐moderate left‐sided ulcerative colitis , 2005, Alimentary pharmacology & therapeutics.

[16]  A. von Ruecker,et al.  Perioperative treatment with human growth hormone down-regulates apoptosis and increases superoxide production in PMN from patients undergoing infrarenal abdominal aortic aneurysm repair. , 2005, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[17]  A. Forbes,et al.  Synergy between TLR9 and NOD2 innate immune responses is lost in genetic Crohn’s disease , 2005, Gut.

[18]  J. Korzenik,et al.  Sargramostim for active Crohn's disease. , 2005, The New England journal of medicine.

[19]  Clive M. Onnie,et al.  Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease , 2005, The Lancet.

[20]  D. Rampton,et al.  Molecular Characterization of Rectal Mucosa‐Associated Bacterial Flora in Inflammatory Bowel Disease , 2005, Inflammatory bowel diseases.

[21]  S. Hanauer,et al.  Infliximab induction and maintenance therapy for ulcerative colitis: the ACT 2 trial , 2005 .

[22]  Joel V Weinstock,et al.  Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. , 2005, Gastroenterology.

[23]  W. Schmiegel,et al.  A Polymorphism of the Bactericidal/Permeability Increasing Protein (BPI) Gene Is Associated With Crohn's Disease , 2005, Journal of clinical gastroenterology.

[24]  J. Remon,et al.  Interleukin-10 producing Lactococcus lactis for the treatment of Crohn??s disease , 2005 .

[25]  P. Rutgeerts,et al.  Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. , 2005, Gastroenterology.

[26]  P. Collin.  Should adults be screened for celiac disease? What are the benefits and harms of screening? , 2005, Gastroenterology.

[27]  B. Wiedenmann,et al.  Escherichia coli Nissle 1917 Distinctively Modulates T-Cell Cycling and Expansion via Toll-Like Receptor 2 Signaling , 2005, Infection and Immunity.

[28]  A. Halverson,et al.  Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. , 2005, Gastroenterology.

[29]  R. Rigby,et al.  Production of interleukin (IL)‐10 and IL‐12 by murine colonic dendritic cells in response to microbial stimuli , 2005, Clinical and experimental immunology.

[30]  J. Korzenik,et al.  An open‐labelled study of granulocyte colony‐stimulating factor in the treatment of active Crohn's disease , 2005, Alimentary pharmacology & therapeutics.

[31]  S. Hanauer,et al.  A randomized, double‐blind, placebo‐controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor‐α, in patients with corticosteroid‐dependent Crohn's disease , 2005 .

[32]  G. Michalopoulos,et al.  Liver regeneration, growth factors, and amphiregulin. , 2005, Gastroenterology.

[33]  Robert W. Summers,et al.  Vomiting in the recently anticoagulated patient , 2004, Gut.

[34]  A. Innes,et al.  Intravenous CDP870, a PEGylated Fab′ fragment of a humanized antitumour necrosis factor antibody, in patients with moderate‐to‐severe Crohn's disease: an exploratory study , 2004, Alimentary pharmacology & therapeutics.

[35]  M. Neurath,et al.  Anti-interleukin-12 antibody for active Crohn's disease. , 2004, The New England journal of medicine.

[36]  J. Feisthammel,et al.  A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis , 2004, Gut.

[37]  P. Brigidi,et al.  Modulation of human dendritic cell phenotype and function by probiotic bacteria , 2004, Gut.

[38]  D. Elliott,et al.  Heligmosomoides polygyrus inhibits established colitis in IL‐10‐deficient mice , 2004, European journal of immunology.

[39]  G. Radford-Smith,et al.  CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial , 2004, Gut.

[40]  Tomohiro Watanabe,et al.  NOD2 is a negative regulator of Toll-like receptor 2–mediated T helper type 1 responses , 2004, Nature Immunology.

[41]  P. Rutgeerts,et al.  A phase III, double-blind, placebo-controlled study of the efficacy, safety, and tolerability of antegren (Natalizumab) in maintaining clinical response and remission in Crohn’s disease (ENACT-2) , 2004 .

[42]  D. Hommes,et al.  Fontolizumab (Huzaf), a humanized anti-IFN-gamma antibody, has clinical activity and excellent tolerability in moderate to severe Crohn’s disease , 2004 .

[43]  Thomas Lengauer,et al.  Genetic variation in DLG5 is associated with inflammatory bowel disease , 2004, Nature Genetics.

[44]  J. Hampe,et al.  Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease , 2004, Gut.

[45]  T. Hibi,et al.  A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. , 2004, Gastroenterology.

[46]  N. Yoshimura,et al.  Selective Granulocyte and Monocyte Adsorptive Apheresis as a First-Line Treatment for Steroid Naïve Patients with Active Ulcerative Colitis: A Prospective Uncontrolled Study , 2004, Digestive Diseases and Sciences.

[47]  H. Herfarth,et al.  Lactobacillus GG in inducing and maintaining remission of Crohn's disease , 2004, BMC gastroenterology.

[48]  P. Brooks,et al.  Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR. , 2004, The Journal of rheumatology.

[49]  S. Akira,et al.  Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. , 2004, Gastroenterology.

[50]  C. O'Morain,et al.  Coeliac disease in Europe , 2003, Alimentary pharmacology & therapeutics.

[51]  M. D'souza,et al.  Microencapsulation of tumor necrosis factor oligomers: a new approach to proinflammatory cytokine inhibition. , 2003, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[52]  R. Playford,et al.  Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. , 2003, The New England journal of medicine.

[53]  J. Boudeau,et al.  Inhibitory effect of probiotic Escherichia coli strain Nissle 1917 on adhesion to and invasion of intestinal epithelial cells by adherent–invasive E. coli strains isolated from patients with Crohn's disease , 2003, Alimentary pharmacology & therapeutics.

[54]  M. Weichenthal,et al.  Inducible and Constitutive &bgr;-Defensins Are Differentially Expressed in Crohn's Disease and Ulcerative Colitis , 2003, Inflammatory bowel diseases.

[55]  I. S. Shaw,et al.  Basiliximab (anti‐CD25) in combination with steroids may be an effective new treatment for steroid‐resistant ulcerative colitis , 2003, Alimentary pharmacology & therapeutics.

[56]  B. Sands,et al.  Repifermin (keratinocyte growth factor‐2) for the treatment of active ulcerative colitis: a randomized, double‐blind, placebo‐controlled, dose‐escalation trial , 2003, Alimentary pharmacology & therapeutics.

[57]  P. Testoni,et al.  A pilot trial of Saccharomyces boulardii in ulcerative colitis , 2003, European journal of gastroenterology & hepatology.

[58]  D. Podolsky,et al.  CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. , 2003, Gastroenterology.

[59]  S. Targan,et al.  A humanized anti-CD3 monoclonal antibody, visilizumab, for treatment of severe steroid-refractory ulcerative colitis: Preliminary results of a phase I study , 2003 .

[60]  G. Greenberg,et al.  Efficacy and safety of a humanized α4β7 antibody in active crohn's disease (CD) , 2003 .

[61]  T. Joh,et al.  Transfection of IL-10 expression vectors into endothelial cultures attenuates α4β7-dependent lymphocyte adhesion mediated by MAdCAM-1 , 2003, BMC gastroenterology.

[62]  An Carbonez,et al.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. , 2003, The New England journal of medicine.

[63]  J. Doré,et al.  Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon , 2003, Gut.

[64]  P. Rutgeerts,et al.  A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. , 2003 .

[65]  S. Scherer,et al.  A third human carnitine/organic cation transporter (OCTN3) as a candidate for the 5q31 Crohn's disease locus (IBD5). , 2003, Biochemical and biophysical research communications.

[66]  David H. Miller,et al.  A controlled trial of natalizumab for relapsing multiple sclerosis. , 2003, The New England journal of medicine.

[67]  Subrata Ghosh,et al.  Natalizumab for active Crohn's disease. , 2003, The New England journal of medicine.

[68]  A. T. Te Velde,et al.  Prevention of colitis by interleukin 10-transduced T lymphocytes in the SCID mice transfer model. , 2002, Gastroenterology.

[69]  J. Korzenik,et al.  Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor , 2002, The Lancet.

[70]  R. Buelow,et al.  Rational design and development of RDP58. , 2002, Current pharmaceutical design.

[71]  Meijia Yang,et al.  A novel human fibroblast growth factor treats experimental intestinal inflammation. , 2002, Gastroenterology.

[72]  C. Prantera,et al.  Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG , 2002, Gut.

[73]  A. Buchman,et al.  Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease , 2002, Gut.

[74]  S. Deventer,et al.  Weighty issues in hepatitis C , 2002, Gut.

[75]  Maria Yazdanbakhsh,et al.  Allergy, parasites, and the hygiene hypothesis. , 2002, Science.

[76]  M. Neurath,et al.  Treatment of T Cell-Dependent Experimental Colitis in SCID Mice by Local Administration of an Adenovirus Expressing IL-18 Antisense mRNA , 2002, The Journal of Immunology.

[77]  M. Neurath,et al.  Treatment of T Cell-Dependent Experimental Colitis in SCID Mice by Local Administration of an Adenovirus Expressing IL-18 Antisense mRNA1 , 2002, The Journal of Immunology.

[78]  S. Deventer,et al.  Blockade of endogenous IL-18 ameliorates TNBS-induced colitis by decreasing local TNF-alpha production in mice. , 2001, Gastroenterology.

[79]  E. Furth,et al.  An open-label trial of the PPARγ ligand rosiglitazone for active ulcerative colitis , 2001, American Journal of Gastroenterology.

[80]  A. Zinsmeister,et al.  Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. , 2001, Gastroenterology.

[81]  S. Targan,et al.  Potent Inhibition of Cytokine Production from Intestinal Lamina Propria T Cells by Phosphodiesterase-4 Inhibitory Thalidomide Analogues , 2001, Journal of Clinical Immunology.

[82]  W. Reinisch,et al.  Extracorporeal photochemotherapy in patients with steroid‐dependent Crohn’s disease: a prospective pilot study , 2001, Alimentary pharmacology & therapeutics.

[83]  A. Forbes,et al.  Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease , 2001, Gut.

[84]  Mourad Sahbatou,et al.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease , 2001, Nature.

[85]  Judy H. Cho,et al.  A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease , 2001, Nature.

[86]  F. Guarner,et al.  Dietary inulin improves distal colitis induced by dextran sodium sulfate in the rat , 2001, American Journal of Gastroenterology.

[87]  M. Moser,et al.  Peroxisome proliferator‐activated receptor γ activators inhibit interleukin‐12 production in murine dendritic cells , 2000 .

[88]  P. Rutgeerts,et al.  Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease , 2000 .

[89]  P. Rutgeerts,et al.  Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. , 2000, Gastroenterology.

[90]  B. Staels,et al.  Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation , 2000, Inflammation Research.

[91]  W. Fiers,et al.  Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. , 2000, Science.

[92]  P. Brigidi,et al.  Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. , 2000, Gastroenterology.

[93]  P. Testoni,et al.  Saccharomyces boulardii in Maintenance Treatment of Crohn’s Disease , 2000, Digestive Diseases and Sciences.

[94]  M. Mckinley,et al.  A preliminary study of growth hormone therapy for Crohn's disease. , 2000, The New England journal of medicine.

[95]  A. Hoerauf,et al.  Antigen-specific cellular hyporesponsiveness in a chronic human helminth infection is mediated by Th3/Tr1-type cytokines IL-10 and transforming growth factor-β but not by a Th1 to Th2 shift , 2000 .

[96]  S. Hanauer,et al.  Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. , 1999, Gastroenterology.

[97]  S. Targan,et al.  An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. , 1999, Gastroenterology.

[98]  T. Horie,et al.  New technique of leukocytapheresis by the use of nonwoven polyester fiber filter for inflammatory bowel disease. , 1999, Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis.

[99]  S. Targan,et al.  Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. , 1999, Gastroenterology.

[100]  B. Rembacken,et al.  Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial , 1999, The Lancet.

[101]  M. Lazar,et al.  A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. , 1999, The Journal of clinical investigation.

[102]  C. Boland,et al.  JC virus DNA is present in the mucosa of the human colon and in colorectal cancers. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[103]  N. Barnich,et al.  Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. , 1998, Gastroenterology.

[104]  B. Staels,et al.  Activation of Proliferator-activated Receptors α and γ Induces Apoptosis of Human Monocyte-derived Macrophages* , 1998, The Journal of Biological Chemistry.

[105]  C. Bennett,et al.  A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. , 1998, Gastroenterology.

[106]  K. Sullivan,et al.  Course of Crohn's disease after allogeneic marrow transplantation. , 1998, Gastroenterology.

[107]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[108]  C. Elson,et al.  Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. , 1997, Gastroenterology.

[109]  M. Ono,et al.  A pilot study of centrifugal leukocyte apheresis for corticosteroid-resistant active ulcerative colitis. , 1997, Internal medicine.

[110]  C. Neut,et al.  Fecal β-D-Galactosidase Production and Bifidobacteria Are Decreased in Crohn's Disease , 1997, Digestive Diseases and Sciences.

[111]  M. Ortner,et al.  Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. , 1997, Gut.

[112]  J. Reimund,et al.  In vitro effects of oxpentifylline on inflammatory cytokine release in patients with inflammatory bowel disease. , 1997, Gut.

[113]  G. Tytgat,et al.  CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study. , 1997, Gut.

[114]  R. Modigliani,et al.  Treatment of severe Crohn's disease with anti‐CD4 monoclonal antibody , 1996, Alimentary pharmacology & therapeutics.

[115]  C. Benjamin,et al.  Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. , 1993, The Journal of clinical investigation.

[116]  F. Finkelman,et al.  A primary intestinal helminthic infection rapidly induces a gut-associated elevation of Th2-associated cytokines and IL-3. , 1993, Journal of immunology.

[117]  D. Podolsky.  Inflammatory bowel disease (Second of two parts) , 1991 .

[118]  J. Korzenik,et al.  Association of glycogen storage disease 1b and Crohn disease: results of a North American survey , 2007, European Journal of Pediatrics.

[119]  J. Stockman.  Treatment of Ulcerative Colitis With a Humanized Antibody to the α4β7 Integrin , 2007 .

[120]  M. Vos,et al.  Two phase 3 studies of alicalorsen (ISIS-2302), an antisense oligonucleotide to human ICAM-1, in the treatment of moderate to severe Crohn's disease , 2005 .

[121]  G. Radford-Smith,et al.  CDP 571 , a humanised monoclonal antibody to tumour necrosis factor a , for moderate to severe Crohn ’ s disease : a randomised , double blind , placebo controlled trial , 2004 .

[122]  Judy H. Cho,et al.  Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. , 2003, Gastroenterology.

[123]  D. Hommes,et al.  Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. , 2002, Gastroenterology.

[124]  A place for TACE , 2002 .

[125]  A. Munakata,et al.  Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: A multicenter study , 2001, Journal of clinical apheresis.

[126]  P. Rutgeerts,et al.  Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. , 2000, Gastroenterology.

[127]  A. Hoerauf,et al.  Antigen-specific cellular hyporesponsiveness in a chronic human helminth infection is mediated by T(h)3/T(r)1-type cytokines IL-10 and transforming growth factor-beta but not by a T(h)1 to T(h)2 shift. , 2000, International immunology.

[128]  J. Korzenik,et al.  Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease. , 2000, Digestive diseases and sciences.